Xinnate
Xinnate is a pharmaceutical development company in Lund, Sweden developing novel, pharmaceutical therapies based on a pioneering technology of immune modulating peptides, that targets dysfunctional healing by controlling presence of microbials and the complex interplay of inflammatory responses. Xinnate runs an ambitious research and clinical program for TCP25 including a clinical study in phase 1b in patients with Epidermolysis bullosa (EB). Late-stage clinical development and commercialization will take place in partnership with one or more leading pharmaceutical companies.
7-day free trial · no credit card
Verified contacts
5
available on Kipplo
LinkedIn employees
6
1 to 10 range
Open roles
—
no listings
Distinct roles
5
indexed titles
Tech stack
0
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 5 verified contacts at Xinnate
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
5 contacts with verified email or phone · masked until revealed.
- MH
Matilda Hugerth
Head of Clinical Development · Research & Development
EmailPhone - NB
Nina Bladh
Head of Cmc Development · Manufacturing & Production
EmailPhone - HH
Helene Hartman
CEO Xinnate Ab · Other
EmailPhone
Showing 3 of 5 verified contacts
Top roles at Xinnate
5 distinct titles indexed · top 5 shown.
- 1board member
- 1ceo xinnate ab
- 1head of clinical development
- 1head of cmc development
- 1science communicator
Sign up to unlock all 5 contacts at Xinnate
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 5 verified contacts at Xinnate
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.